These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2511711)

  • 41. [Activity of rifampicin on experimental tuberculosis in mice. The development of resistance to rifampicin. Therapeutic effects of combinations of different drugs with rifampicin].
    Grumbach F
    Antibiot Chemother; 1970; 16():392-405. PubMed ID: 5002305
    [No Abstract]   [Full Text] [Related]  

  • 42. The effect of chemotherapy for tuberculosis on immunity to tuberculosis.
    Lefford MJ; McGregor DD
    J Infect Dis; 1974 Apr; 129(4):473-6. PubMed ID: 4206250
    [No Abstract]   [Full Text] [Related]  

  • 43. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis.
    March F; Garriga X; Rodríguez P; Moreno C; Garrigó M; Coll P; Prats G
    Clin Infect Dis; 1997 Nov; 25(5):1044-7. PubMed ID: 9402354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.
    Sharma A; Sharma S; Khuller GK; Kanwar AJ
    Int J Antimicrob Agents; 2009 Sep; 34(3):226-30. PubMed ID: 19505802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rifampin: characteristics and role in the chemotherapy of tuberculosis.
    Vall-Spinosa A; Lester TW
    Ann Intern Med; 1971 May; 74(5):758-60. PubMed ID: 4997716
    [No Abstract]   [Full Text] [Related]  

  • 46. [Incidence and significance of positive fluorescent bacilloscopy associated with negative cultures during treatment based on isoniazid or rifomycin in tubercular patients treated in the sanatorium].
    Augier J; Parrot R; Gillet P
    Acta Tuberc Pneumol Belg; 1969; 60(3):417-29. PubMed ID: 4984422
    [No Abstract]   [Full Text] [Related]  

  • 47. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 48. Rifampicin: a first line tuberculostatic drug. A critical review and appraisal.
    Saerens EJ
    Acta Tuberc Pneumol Belg; 1972; 63(6):516-28. PubMed ID: 4206441
    [No Abstract]   [Full Text] [Related]  

  • 49. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
    Dutt M; Khuller GK
    J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary and acquired drug resistance in Mycobacterium tuberculosis strains in western region of Libyan Arab Jamahiriya.
    Elghoul MT; Joshi RM; Rizghalla T
    Trop Geogr Med; 1989 Oct; 41(4):304-8. PubMed ID: 2517554
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New approaches to the treatment of latent tuberculosis.
    Sterling TR
    Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Basic mechanisms of chemotherapy.
    Mitchison DA
    Chest; 1979 Dec; 76(6 Suppl):771-81. PubMed ID: 92392
    [No Abstract]   [Full Text] [Related]  

  • 53. [Effect of tuberculostatic agents and sodium succinate on the functional state of liver mitochondria in tuberculosis].
    Sokirko TA
    Vopr Med Khim; 1987; 33(4):83-6. PubMed ID: 3660747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effect of drug resistance of Mycobacterium tuberculosis on the therapeutic results of a drug to which sensitivity is retained(experimental data)].
    Belogurova VP; Ivanitskaia NN
    Antibiotiki; 1970 Feb; 15(2):154-7. PubMed ID: 4986204
    [No Abstract]   [Full Text] [Related]  

  • 55. The pathogenicity of Mycobacterium tuberculosis during chemotherapy.
    Clancy LJ; Kelly P; O'Reilly L; Byrne C; Costello E
    Eur Respir J; 1990 Apr; 3(4):399-402. PubMed ID: 2114307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Rifampicine in tuberculosis. Peculiarity of its experimental activity and new therapeutic prospects].
    Le Lirzin M; Grumbach F
    Pathol Biol (Paris); 1972 Oct; 20(19):785-92. PubMed ID: 4628424
    [No Abstract]   [Full Text] [Related]  

  • 57. Longitudinal whole genome analysis of pre and post drug treatment Mycobacterium tuberculosis isolates reveals progressive steps to drug resistance.
    Datta G; Nieto LM; Davidson RM; Mehaffy C; Pederson C; Dobos KM; Strong M
    Tuberculosis (Edinb); 2016 May; 98():50-5. PubMed ID: 27156618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of tuberculosis.
    Bates JH
    Adv Intern Med; 1975; 20():1-21. PubMed ID: 46687
    [No Abstract]   [Full Text] [Related]  

  • 59. Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis.
    Khor M; Lowrie DB; Coates AR; Mitchison DA
    Br J Exp Pathol; 1986 Aug; 67(4):587-96. PubMed ID: 3091058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug-resistance of Mycobacterium tuberculosis in Patras, Greece.
    Trakada G; Tsiamita M; Spiropoulos K
    Monaldi Arch Chest Dis; 2004; 61(1):65-70. PubMed ID: 15366340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.